GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
Vivimed Labs Ltd
results for FY 2025-2026
RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 17 Jul 2026, 06:23 PM IST  ·  BSE ID: 89e96e18-f56b-49cb-8d27-fc8763fecee0
View Original BSE Filing (PDF)
💡
In Simple Terms
Vivimed Labs reported a significant annual loss, and its old management team has been replaced by an insolvency professional.
🤖 AI Summary
  • Vivimed Labs Ltd approved audited financial results for the quarter and year ending March 31, 2026.
  • The company reported a consolidated net loss of Rs. 1,763.35 Million for the fiscal year 2025-2026.
  • The Board of Directors' powers are suspended since April 15, 2026, due to Corporate Insolvency Resolution Process (CIRP).
  • An Interim Resolution Professional (IRP) has been appointed and is now vested with the management and control.
  • During FY26, inventory worth Rs. 233.08 Million was written down and charged to the Profit and Loss Statement.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from Operations (FY26)
Rs. 690.55 Million
Not comparable — limited prior period data.
Consolidated Profit for the period/year (FY26)
(Rs. 1,763.35) Million
Not comparable — limited prior period data.
Standalone Profit for the period/year (FY26)
(Rs. 1,716.11) Million
Not comparable — limited prior period data.
Inventory Written Down (FY26)
Rs. 233.08 Million
🏢 How This Affects the Company
📈
Business Impact
Ongoing operations are now managed by an Interim Resolution Professional (IRP) under CIRP, affecting business continuity and decision-making.
💰
Financial Impact
The company recorded a consolidated net loss of Rs. 1,763.35 Million for FY26, with inventories amounting to Rs. 233.08 Million written down.
⚙️
Operational Impact
The operational control has shifted from the Board to the IRP/RP due to CIRP, impacting day-to-day management and strategic direction.
⚠️
Risk Impact
The initiation of CIRP on April 15, 2026, and ongoing CBI investigation increase regulatory and financial risks for the company.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the company's significant losses for FY26 and the ongoing CIRP, which has shifted management control to an Interim Resolution Professional.
🔍
Management Signal
The filing confirms the complete transfer of management and control to the Interim Resolution Professional, signaling the ongoing formal insolvency process.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Next update from Interim Resolution Professional on CIRP proceedings
Committee of Creditors (CoC) meeting outcomes for resolution plan
Updates on the One Time Settlement with IFC and Bank of Baharain and Kuwait
HIGH RISK Company is under Corporate Insolvency Resolution Process (CIRP) and reported substantial losses for FY26.
💡 Investor Takeaway
Vivimed Labs reported a consolidated net loss of Rs. 1,763.35 Million for FY26. The company is under Corporate Insolvency Resolution Process (CIRP) since April 15, 2026, resulting in the suspension of the Board's powers and appointment of an IRP.
⚖️ Strengths & Concerns

⚠️ Concerns

  • Consolidated Profit for the year ended 31.03.2026 was (Rs. 1,763.35) Million, indicating significant financial losses.
  • The Company is currently under Corporate Insolvency Resolution Process (CIRP) initiated on April 15, 2026, suspending board powers.
📅 Company Track Record
Vivimed Labs had a board meeting scheduled on July 17, 2026, to consider Q4 FY26 results, as informed to BSE on July 14, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Vivimed Labs' consolidated net loss for the fiscal year 2025-2026?
Vivimed Labs reported a consolidated net loss of Rs. 1,763.35 Million for the fiscal year ended March 31, 2026.
When did the Corporate Insolvency Resolution Process (CIRP) commence for Vivimed Labs?
The Corporate Insolvency Resolution Process (CIRP) for Vivimed Labs commenced on April 15, 2026.
Who is currently vested with the management and control of Vivimed Labs?
The Interim Resolution Professional (IRP) / Resolution Professional (RP) is currently vested with the management and control of Vivimed Labs.
What was the amount of inventory written down by Vivimed Labs during FY26?
During the year ended March 31, 2026, inventory amounting to Rs. 233.08 Million was written down.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.